Galera to Present at Jefferies Healthcare Conference
02. Juni 2022 07:00 ET
|
Galera Therapeutics
MALVERN, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Announces Oral Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Detailing Results from Phase 3 ROMAN Trial of Avasopasem
26. Mai 2022 17:00 ET
|
Galera Therapeutics
Avasopasem produced clinically meaningful, statistically significant reduction of severe oral mucositis (SOM) in patients with locally advanced head and neck cancer receiving radiotherapy Company on...
Galera Reports First Quarter 2022 Financial Results and Recent Corporate Updates
16. Mai 2022 07:30 ET
|
Galera Therapeutics
Company plans to submit a New Drug Application (NDA) for avasopasem for the treatment of radiotherapy-induced severe oral mucositis (SOM) by end of 2022 Data from its Phase 3 ROMAN trial of...
Galera Announces Plan to Submit Avasopasem NDA by Year End
16. Mai 2022 07:00 ET
|
Galera Therapeutics
MALVERN, Pa., May 16, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Announces Topline Results from Phase 2a AESOP Trial of Avasopasem for Chemoradiotherapy-Induced Esophagitis
02. Mai 2022 07:00 ET
|
Galera Therapeutics
Incidence of Grade 3 esophagitis substantially reduced in patients treated with avasopasem compared to literature No Grade 4 or 5 esophagitis in patients treated with avasopasem MALVERN, Pa, May...
Galera to Present at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
27. April 2022 10:00 ET
|
Galera Therapeutics
MALVERN, Pa., April 27, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Updates
10. März 2022 07:00 ET
|
Galera Therapeutics
Positive Phase 3 ROMAN trial of avasopasem for severe oral mucositis met primary and secondary endpoint; Company intends to meet with FDA in 2022 about NDA submission Data readouts from AESOP in...
Galera to Present at H.C. Wainwright BioConnect Conference
06. Januar 2022 07:00 ET
|
Galera Therapeutics
MALVERN, Pa., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Announces Primary Endpoint Met Statistical Significance in Corrected Topline Efficacy Data of Phase 3 ROMAN Trial of Avasopasem
14. Dezember 2021 07:00 ET
|
Galera Therapeutics
Corrected topline Phase 3 ROMAN data demonstrate primary endpoint achieved statistical significance in reducing the incidence of radiotherapy-induced severe oral mucositis (p=0.045)Topline results...
Galera to Present at Two Upcoming Investor Conferences in November
15. November 2021 07:00 ET
|
Galera Therapeutics
MALVERN, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...